Form 4: Generation Bio Co. Director Acquires Stock Options

Ronald Harold Wilfred Cooper, a director of Generation Bio Co., was granted stock options to purchase 60,000 shares of common stock on June 6, 2024.

Summary

• Ronald Harold Wilfred Cooper, a director at Generation Bio Co. (GBIO), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 6, 2024, where Cooper was granted stock options.
• These options allow Cooper to purchase 60,000 shares of Generation Bio Co. common stock at an exercise price of $3.32 per share.
• The options vest fully on the earlier of June 6, 2025, or the date of Generation Bio's 2025 annual meeting of stockholders.
• The options expire on June 5, 2034.
• Following the reported transaction, Cooper directly owns 60,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. The granting of stock options is a routine event and doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholders and incentivizing long-term growth.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in the biotech industry, similar to companies like Amgen and Biogen, where stock options are used to attract and retain talent.
• The vesting schedule of one year is also fairly typical, aligning with industry norms for incentivizing performance over the short to medium term.

Stakeholder Impact

• The granting of stock options to a director can potentially align their interests with those of shareholders.

Key Dates